Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) structurally related to GHRP-6. It was investigated as a GH secretagogue in limited preclinical studies but never advanced to meaningful clinical development. Very little published data exists, and it remains an obscure research compound with no approved indication.
Category: Growth Hormone Secretagogue. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical only. No clinical trials registered or completed.
Alexamorelin is believed to act as a ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone release from the anterior pituitary. Like other GHRPs, it likely works through both hypothalamic and direct pituitary mechanisms. Detailed pharmacological characterization is sparse in the published…
Safety considerations: No human safety data available; Expected class effects of GHRPs: potential appetite stimulation, cortisol elevation, prolactin elevation; Unknown long-term safety profile.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~714 g/mol |
|---|---|
| Production method | synthetic |
| Anti-doping status | Prohibited in sport (WADA) |
| US regulatory status | Not FDA-approved. Research chemical only. |
Related peptides: Ipamorelin, CJC-1295, Sermorelin.
Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) that was explored in limited preclinical research. It never progressed to clinical trials and has very little published data.
There is insufficient published data to make meaningful comparisons. More established GHRPs such as GHRP-6, GHRP-2, hexarelin, and ipamorelin have substantially more research behind them.
On the PeptideAtlas A–F scale, Alexamorelin is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical only. No clinical trials registered or completed.
Alexamorelin is believed to act as a ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone release from the anterior pituitary. Like other GHRPs, it likely works through both hypothalamic and direct pituitary mechanisms. Detailed pharmacological characterization is sparse in the published literature.